{"id":821991,"date":"2025-03-05T08:47:05","date_gmt":"2025-03-05T13:47:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/market-news-alertnuvectis-pharmas-nxp900-demonstrates-superior-efficacy-in-nsclc-when-combined-with-tagrisso-in-cleveland-clinic-study-following-new-buy-recommendation\/"},"modified":"2025-03-05T08:47:05","modified_gmt":"2025-03-05T13:47:05","slug":"market-news-alertnuvectis-pharmas-nxp900-demonstrates-superior-efficacy-in-nsclc-when-combined-with-tagrisso-in-cleveland-clinic-study-following-new-buy-recommendation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/market-news-alertnuvectis-pharmas-nxp900-demonstrates-superior-efficacy-in-nsclc-when-combined-with-tagrisso-in-cleveland-clinic-study-following-new-buy-recommendation\/","title":{"rendered":"Market News Alert:Nuvectis Pharma\u2019s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation"},"content":{"rendered":"

<\/p>\n

Market News Alert:<\/b>Nuvectis Pharma\u2019s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation<\/b><\/p>\n

Cleveland Clinic research provides further positive validation Nuvectis Pharma’s* NXP900 cancer-fighting potential, showing enhanced efficacy when combined with AstraZeneca’s blockbuster drug Tagrisso\u00ae in EGFR+ lung cancer models. New $18 price target and buy recommendation from Lucid Capital Markets implies 200%+ potential upside as Phase 1b trial approaches<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nMarket News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso\u00ae) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to decreased cancer cell proliferation and increased apoptosis compared to osimertinib alone.\n<\/p>\n

\nAccording to the company, this research from Prof. Ruth Keri\u2019s laboratory at Cleveland Clinic provides critical independent validation of previous findings from AstraZeneca researchers, confirming that NXP900 can effectively combat resistance mechanisms that limit the effectiveness of EGFR inhibitors like Tagrisso, which generates over $5 billion in annual sales.\n<\/p>\n

\nNXP900, an oral SRC\/YES1 kinase inhibitor with a unique mechanism that inhibits both catalytic and scaffolding functions, shows promise in addressing resistance to current standard-of-care treatments. The company is also advancing NXP800, a GCN2 activator in Phase 1b trials for platinum-resistant, ARID1a-mutated ovarian cancer, with encouraging interim data showing partial response and stable disease in several patients.\n<\/p>\n

\nIndustry analysts seem to have taken notice of Nuvectis\u2019s potential. In February 2025, Lucid Capital Markets reportedly initiated coverage with a BUY rating and an $18 price target, projecting peak sales of over $900 million for NXP900 across multiple cancer indications. This represents significant potential upside potential from current levels. With multiple catalysts expected in 2025, including completion of the NXP900 Phase 1a study, initiation of Phase 1b trials, and updated NXP800 clinical data in Q2, Nuvectis seems to be a fascinating company to watch in 2025.\n<\/p>\n

Recent News from Nuvectis<\/b><\/p>\n